MHC-Unrestricted Lysis of MUC1-Expressing Cells by Human Peripheral Blood Mononuclear Cells

REFERENCES

• Ahmed S. A., Gogal R.M., Walsh J.E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Meth. 1994; 170: 211–224
   PubMed Web of Science ®Google Scholar
• Alajez N. M., Schmielau J., Alter M. D., Cascio M., Finn O. J. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 2005; 105: 4583–4589
   Google Scholar
• Apostolopoulos V., Karanikas V., Haurum J. S., McKenzie I. F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 1997; 159: 5211–5218
   PubMed Web of Science ®Google Scholar
• Barnd D. L., Lan M. S., Metzgar R.S., Finn O. J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 1989; 86: 7159–7163
   PubMed Web of Science ®Google Scholar
• Brossart P., Heinrich K. S., Stuhler G., Behnke L., Reichardt V. L., Stevanovic S., Muhm A., Rammensee H. G., Kanz L., Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309–4317
   PubMed Web of Science ®Google Scholar
• Bu D., Domenech N., Lewis J., Taylor-Papadimitriou J., Finn O. J. Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition. J. Immunother. 1993; 14: 127–135
   Web of Science ®Google Scholar
• Domenech N., Henderson R. A., Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J.Immunol. 1995; 155: 4766–4774
   PubMed Web of Science ®Google Scholar
• Finn O. J. Antigen-specific, MHC-unrestricted T cells. Biotherapy 1992; 4: 239–249
   PubMedGoogle Scholar
• Gendler S. J. MUC1, the Renaissance molecule. J Mammary Gland Biol. Neoplasia 2001; 3: 339–353
   Google Scholar
• Gendler S. J., Lancaster C. A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E. N., Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 1990; 265: 15286–15293
   PubMed Web of Science ®Google Scholar
• Gendler S. J., Spicer A.P., Lalaini E. N., Duhig T., Peat N., Burchell J., Pemberton L., Boshell M., Taylor-Papadimitriou J. Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis. 1991; 144: S42–S47
   PubMed Web of Science ®Google Scholar
• Hanisch F. G., Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000; 10: 439–449
   PubMed Web of Science ®Google Scholar
• Ioannides C. G., Fisk B., Jerome K. R., Irimura T., Wharton J. T., Finn O. J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 1993; 151: 3693–3703
   PubMed Web of Science ®Google Scholar
• Kornbluth J., Flomenberg N., Dupont B. Cell surface phenotype of a cloned line of natural killer cells. J. Immunol. 1982; 129: 2831–2837
   PubMed Web of Science ®Google Scholar
• Orr M. K., Burnside J. S., Phillips C. A., Philip R., Dombrowski K. E., Wright S. E. MHC-restricted presentation of a single repeat of MUC1 mucin. Immunol. Invest. 2007; 36: 271–283
   PubMed Web of Science ®Google Scholar
• Plum S. M., Hanson A. D., Volker K. M., Vu H. A., Sim B. K., Fogler W. E., Fortier A.H. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an othrotopic murine mammary carcinoma model. Clincal Cancer Res. 2003; 9: 4619–4626
   Google Scholar
• Quinlin I. S., Burnside J. S., Dombrowski K. E., Phillips C. A., Dolby N., Wright S. E. Context of MUC1 epitope: immunogenicity. Oncol. Rep. 2007; 17: 453–456
   Google Scholar
• Reddish M., MacLean G.D., Koganty R.R., Kan-Mitchell J., Jones V., Mitchell M.S., Longenecker B.M. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer 1998; 76: 817–823
   PubMed Web of Science ®Google Scholar
• Roehm N. W., Rodgers G. H., Hatfield S. M., Glasebrook A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Meth. 1991; 142: 257–265
   PubMed Web of Science ®Google Scholar
• Thiele D. L., Lipsky P. E. The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells. Immunol. Today 1989; 10: 375–381
   PubMedGoogle Scholar
• Visonneau S., Cesano A., Porter D. L., Luger S. L., Schuchter L., Kamoun M., Torosian M. H., Duffy K., Sickles C., Stadtmauer E. A., Santoli D. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin. Cancer. Res. 2000; 6: 1744–1754
   PubMed Web of Science ®Google Scholar
• Wright S. E., Kilinski L., Talib S., Lowe K. E., Burnside J. S., Wu J. Y., Dolby N., Dombrowski K. E., Lebkowski J. S., Philip R. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J. Immunother. 2000; 23: 2–10
   Google Scholar
• Wright S. E., Khaznadar R., Wang Z., Quinlin I. S., Rewers-Felkins K. A., Phillips C. A., Patel S. Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand. J. Immunol. 2008; 67(1)24–29, Epub 2007 Nov 15.
   PubMed Web of Science ®Google Scholar